عربي English Türkçe اردو فارسى
Logo
Latest News
Varieties

Japan’s Royal Family Makes Instagram Debut

Japan's Princess Aiko, the daughter of Emperor Naruhito and Empress Masako, poses for the media at the Japanese Red Cross Society as she begins to work on April 1, 2024. (AFP)
Japan's Princess Aiko, the daughter of Emperor Naruhito and Empress Masako, poses for the media at the Japanese Red Cross Society as she begins to work on April 1, 2024. (AFP)
TT
TT

Japan’s Royal Family Makes Instagram Debut

Japan's Princess Aiko, the daughter of Emperor Naruhito and Empress Masako, poses for the media at the Japanese Red Cross Society as she begins to work on April 1, 2024. (AFP)
Japan's Princess Aiko, the daughter of Emperor Naruhito and Empress Masako, poses for the media at the Japanese Red Cross Society as she begins to work on April 1, 2024. (AFP)

Japan's royal family is now on Instagram -- but don't expect any candid selfies from its official account, which went live Monday in a cautious social media debut for the ancient monarchy.

The first 19 posts are formally staged photos and videos of Emperor Naruhito and Empress Masako carrying out royal duties at recent public appearances.

Nonetheless, more than 160,000 users have followed the Imperial Household Agency (IHA) account, which was announced a week ago but set to private until Monday.

The Japanese monarchy has mythological origins stretching back more than two millennia, and any public criticism of the emperor remains taboo in the country.

By joining social media, the institution hopes to spark interest among younger generations about what the imperial family does, an IHA spokesperson confirmed to AFP.

But, perhaps predictably, the posts under the Instagram handle kunaicho_jp contain no behind-the-scenes juice.

Strictly factual captions explain what the emperor did on what day, from meeting foreign dignitaries to admiring bonsai trees, with comments moderated.

The account does not follow any other users, and has so far not ventured into Instagram Stories.

"The IHA is on Instagram! I thought it was an April Fools' prank!" one X user wrote in reaction to the launch.

"When I heard the IHA created an Instagram account, I quickly checked it out. But of course the emperor wouldn't post 'today's lunch (heart emoji)' or anything like that," wrote another.

Some users joked it was good the royals had chosen the more "civilized" Instagram over X, formerly Twitter.

Naruhito ascended the Chrysanthemum throne in 2019 in a tradition-laden ceremony after his highly popular father became the first emperor to abdicate in over two centuries.

Other monarchies have created social media accounts, including Britain's royals, who have recently been at the center of a storm of rumors and conspiracy theories.

The manipulation of a family photograph the palace released to the media fueled online speculation over the whereabouts of Catherine, Princess of Wales, who later revealed she had been diagnosed with cancer.

Most Viewed

 
 
Varieties

Ozempic Hailed as 'Fountain of Youth' that Slows Aging

The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
TT
TT

Ozempic Hailed as 'Fountain of Youth' that Slows Aging

The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
The is available under the brand names Wegovy and Ozempic (Photo by Reuters)

The anti-obesity drug Ozempic could slow down ageing and has “far-reaching benefits” beyond what was imagined, researchers have suggested.

Multiple studies have found semaglutide (available under the brand names Wegovy and Ozempic) reduced the risk of death in people who were obese or overweight and had cardiovascular disease without diabetes, The Independent reported.

Responding to research published in JACC, the flagship journal of the American College of Cardiology, Professor Harlan M Krumholz from the Yale School of Medicine, said: “Semaglutide, perhaps by improving cardiometabolic health, has far-reaching benefits beyond what we initially imagined.”

He added: “These ground-breaking medications are poised to revolutionise cardiovascular care and could dramatically enhance cardiovascular health.”

Multiple reports also quoted Professor Krumholz saying: “Is it a fountain of youth?”

He said: “I would say if you’re improving someone’s cardiometabolic health substantially, then you are putting them in a position to live longer and better.

“It’s not just avoiding heart attacks. These are health promoters. It wouldn’t surprise me that improving people’s health this way actually slows down the ageing process.”

The studies, presented at the European Society of Cardiology Conference 2024 in London, were produced from the Select trial which studied 17,604 people aged 45 or older who were overweight or obese and had established cardiovascular disease but not diabetes.

They received 2.4 mg of semaglutide or a placebo and were tracked for more than three years.

A total of 833 participants died during the study with 5 percent of the deaths were related to cardiovascular causes and 42 per cent from others.

Infection was the most common cause death beyond cardiovascular, but it occurred at a lower rate in the semaglutide group than the placebo group.

People using the weight-loss drug were just as likely to catch Covid-19, but they were less likely to die from it – 2.6 percent dying among those on semaglutide versus 3.1 per cent on the placebo.

Researchers found women experienced fewer major adverse cardiovascular events, but semaglutide “consistently reduced the risk” of adverse cardiovascular outcomes regardless of sex.

Dr Benjamin Scirica, lead author of one of the studies and a professor of cardiovascular medicine at Harvard Medical School, said: “The robust reduction in non-cardiovascular death, and particularly infections deaths, was surprising and perhaps only detectable because of the Covid-19-related surge in non-cardiovascular deaths.

“These findings reinforce that overweight and obesity increases the risk of death due to many etiologies, which can be modified with potent incretin-based therapies like semaglutide.”

Dr Jeremy Samuel Faust, an emergency medicine physician at Brigham and Women’s Hospital, praised the researchers for adapting the study to look at Covid-19 when the pandemic started.

He said the findings that the weight-loss drug to reduce Covid-19 mortality rates were “akin to a vaccine against the indirect effects of a pathogen.”